Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction.

Activation of guanine nucleotide-binding protein (G protein)-coupled receptors is believed to involve conformational change that exposes a domain for G protein coupling at the cytosolic surface of the helical confluence, although the mechanisms for achieving this are not well understood. This conformational change can be achieved by docking a diverse variety of agonist ligands, known to occur by interacting with different regions of these receptors. In this study, we focus on the importance of a specific basic residue (Lys187) within the second extracellular loop of the receptor for the peptide hormone, cholecystokinin. Alanine-replacement and charge-reversal mutagenesis of this residue showed that it had no effect on the binding of natural peptide and nonpeptidyl ligands of this receptor but markedly interfered with agonist-stimulated signaling. It was demonstrated that this negative effect on biological activity could be eliminated with the truncation of the first 30 residues of the amino-terminal tail of this receptor. Complementary charge-reversal mutagenesis of each of the five conserved acidic residues within this region of the receptor in the presence of the charge-reversed Lys187 revealed that only the Asp5 mutant fully reversed the negative functional impact of the Lys187 charge reversal. Thus, we have demonstrated that a basic residue within the second extracellular loop of the cholecystokinin receptor interacts with a specific acidic residue within the amino terminus of this receptor. This residue-residue interaction is nicely accommodated within a new molecular model of the agonist-occupied cholecystokinin receptor.

[1]  L. Miller,et al.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.

[2]  B. Maigret,et al.  Arginine 197 of the cholecystokinin‐A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin , 2008, Protein science : a publication of the Protein Society.

[3]  T. Lybrand,et al.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. , 2006, Journal of medicinal chemistry.

[4]  L. Miller,et al.  Key Differences in Molecular Complexes of the Cholecystokinin Receptor with Structurally Related Peptide Agonist, Partial Agonist, and Antagonist , 2004, Molecular Pharmacology.

[5]  Laerte Oliveira,et al.  Sequence analysis reveals how G protein–coupled receptors transduce the signal to the G protein , 2003, Proteins.

[6]  G Vriend,et al.  Correlated Mutation Analyses on Very Large Sequence Families , 2002, Chembiochem : a European journal of chemical biology.

[7]  T. Lybrand,et al.  Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. , 2002, Molecular pharmacology.

[8]  T. Lybrand,et al.  Refinement of the Structure of the Ligand-occupied Cholecystokinin Receptor Using a Photolabile Amino-terminal Probe* , 2001, The Journal of Biological Chemistry.

[9]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[10]  M. Pellegrini,et al.  Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy. , 1999, Biochemistry.

[11]  L. Miller,et al.  Structurally similar small molecule photoaffinity CCK-A agonists and antagonists as novel tools for directly probing 7TM receptors-ligand interactions. , 1998, Bioorganic & medicinal chemistry letters.

[12]  T. Lybrand,et al.  Direct Identification of a Second Distinct Site of Contact between Cholecystokinin and Its Receptor* , 1998, The Journal of Biological Chemistry.

[13]  T. Lybrand,et al.  Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.

[14]  L. Miller,et al.  Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.

[15]  L. F. Kolakowski,et al.  Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor. , 1996, Molecular pharmacology.

[16]  L. Miller,et al.  Multiple Extracellular Loop Domains Contribute Critical Determinants for Agonist Binding and Activation of the Secretin Receptor* , 1996, The Journal of Biological Chemistry.

[17]  N. Vaysse,et al.  Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. , 1995, Biochemical and biophysical research communications.

[18]  L. Miller,et al.  Dual pathways of internalization of the cholecystokinin receptor , 1995, The Journal of cell biology.

[19]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[20]  R. Jensen,et al.  Importance of sulfation of gastrin or cholecystokinin (CCK) on affinity for gastrin and CCK receptors , 1989, Peptides.

[21]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[22]  R. Jensen,et al.  The importance of the amino acid in position 32 of cholecystokinin in determining its interaction with cholecystokinin receptors on pancreatic acini. , 1981, Biochimica et biophysica acta.

[23]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[24]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Lybrand,et al.  Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. , 2004, Molecular pharmacology.

[26]  L. Miller,et al.  Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: specific mono-reactive receptor constructs examine charge-sensitivity of loop regions. , 2003, Receptors & channels.